The Use of Genetic Testing Information in the Insurance Industry: An Ethical and Societal Analysis of Public Policy Options

Original Paper

Abstract

Informed by a search of the literature about the usage of genetic testing information (GTI) by insurance companies, this paper presents a practical ethical analysis of several distinct public policy options that might be used to govern or constrain GTI usage by insurance providers. As medical research advances and the extension to the Human Genome Project (2016, https://en.wikipedia.org/wiki/Human_Genome_Project_-_Write) moves to its fullness over the next decade, such research efforts will allow the full synthesis of human DNA to be connected to predictive health dispositions. As testing costs fall, there will be ever more pressure for citizens to disclose GTI. Genetic testing information is integral to future medical care because it can be used to better assess individually tailored medical therapies as well as to allow a more informed risk analysis by the insurance industry, which in some countries such as the USA underwrites a majority of citizen medical expenses. As discussed in this examination, the revelation of people’s uniquely personal GTI to insurers has enormous societal implications. The major contribution of the paper is to offer policy makers and concerned citizens a nuanced articulation of the basic options to regulate GTI, with a special consideration for ethical fairness and equity. As genetic-based medicine blossoms and pressures to reduce healthcare costs increase, there will be an ever greater impetus for countries to revisit their genetic testing policies. Organizations and policy makers striving to create GTI oversights perceived to be both “fair and effective” need to be aware of the ethical perspectives discussed in this paper.

Keywords

Genetic testing Health insurance Healthcare ethics Discrimination Applied ethics Distributive justice Health information privacy 

References

  1. Affordable Health Care for America Act. (2010). HR 3590 amended as Health Care and Education Reconciliation Act. (December).Google Scholar
  2. Almqvist, E., Bloch, M., Brinkman, R., Craufurd, D., & Hayden, M. (1999). A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease. American Journal of Human Genetics, 64, 1293–1304.Google Scholar
  3. Apel, K.-O. (1988). Diskurs und Verantwortung: Das Problem des Übergangs zur postkonventionellen Moral. Frankfurt am Main: Suhrkamp.Google Scholar
  4. Barnett, T., Bass, K., Brown, G., & Hebert, F. J. (1998). Ethical ideology and the ethical judgments of marketing professionals. Journal of Business Ethics, 17(May), 715–723.Google Scholar
  5. Billings, P., Kohn, M., de Cuevas, M., Beckwith, J., Alper, J., & Natowicz, M. (1992). Discrimination as a consequence of genetic testing. American Journal of Human Genetics, 50, 476–482.Google Scholar
  6. Bird, T. (1999). Outrageous fortune: The risk of suicide in genetic testing for Huntington disease. American Journal of Human Genetics, 64, 1289–1292.Google Scholar
  7. Birnbacher, D. (1983). Hans Jonas, das Prinzip Verantwortung. Zeitschrift für Philosophische Forschung, 37, 144–146.Google Scholar
  8. Borna, S., & Avila, S. (1999). Genetic information: Consumers’ right to privacy versus insurance companies’ right to know. A public opinion survey. Journal of Business Ethics, 19(4), 355–362.Google Scholar
  9. Bowie, N. (1999). Business ethics: A Kantian perspective. Malden, MA: Blackwell Publishers.Google Scholar
  10. Bowie, N. (2002). Ethical reasoning in practice: A Kantian approach to business ethics. In T. Donaldson, P. H. Werhane, & M. Cording (Eds.), Ethical issues in business: A philosophical approach (pp. 61–71). New Jersey: Prentice Hall.Google Scholar
  11. Brockett, P., & Tankersley, S. (1997). The genetics revolution, economics, ethics and insurance. Journal of Business Ethics, 16(15), 1661–1676.Google Scholar
  12. Buchanan, A., Brock, D., Daniels, N., & Winkler, D. (2000). From chance to choice. Cambridge, UK: Cambridge University Press.Google Scholar
  13. Callahan, J. (1990). From the ‘applied” to the practical: Teaching ethics for use. American Philosophical Association Newsletter on Teaching Philosophy, 90(1), 29–34.Google Scholar
  14. Cardon, J., & Hendel, I. (2001). Asymmetric information in health insurance: Evidence from the National Medical Expenditure Survey. Rand Journal of Economics, 32(3), 408–427.Google Scholar
  15. CDC (Center for Disease Control) (2017). Genomic testing. Retrieved March 18, 2017 from http://www.cdc.gov/genomics/gtesting/
  16. Crocker, K., & Snow, A. (2013). The theory of risk classification. In G. Dionne (Ed.), Handbook of Insurance. New York: Springer.Google Scholar
  17. Deloitte. (2013). Health insurance market overview. Deloitte Consulting LLP. (August).Google Scholar
  18. Dionne, G., & Rothschild, C. (2014). Economic effects of risk classification bans. The Geneva Risk and Insurance Review, 39, 184–221.Google Scholar
  19. Dunfee, T. W., Smith, C., & Ross, W. T. (1999). Social contracts and marketing ethics. Journal of Marketing, 63(3), 14–32.Google Scholar
  20. Durnin, M., Hoy, M., & Ruse, M. (2012). Genetic testing and insurance: The complexity of adverse selection. Ethical Perspectives, 19(1), 123–154.Google Scholar
  21. Ferrell, O.C., & Ferrell, L. (2008) A macromarketing ethics framework: stakeholder orientation and distributive justice. Journal of Macromarketing, 28(1), 24–32.Google Scholar
  22. Ferrell, O. C., & Gresham, L. G. (1985). A contingency framework for understanding ethical decision making in marketing. Journal of Marketing, 49(3), 87–96.Google Scholar
  23. Forsyth, D. R. (1992). Judging the morality of business practices: The influence of personal moral philosophies. Journal of Business Ethics, 11(4), 461–470.Google Scholar
  24. Frankena, W. (1963). Ethics. Englewood Cliffs, NJ: Prentice Hall.Google Scholar
  25. Fukuyama, F. (2002). Our posthuman future. Consequences of the biotechnology revolution. New York: Farrar, Straus & Giroux.Google Scholar
  26. Geller, L., Alper, J., Billings, P., Barash, C., Beckwith, J., & Natowics, M. (1996). Individual, family, and societal dimensions of genetic discrimination: A case study analysis. Science and Engineering Ethics, 2(1), 71–88.Google Scholar
  27. Genetic Information Nondiscrimination Act of 2008 (GINA). (2008). Pub. L. No. 110-233.Google Scholar
  28. Hare, Richard M. (1991). Moral thinking: Its levels, method and point. Oxford: Claredon.Google Scholar
  29. Harris, J. (1992). Wonderwoman and superman; the ethics of human biotechnology. Oxford: Oxford University Press.Google Scholar
  30. Harvard Law Review. (2009). Health law—Genetics—Congress restricts use of genetic information by insurers and employers.—Genetic Information Nondiscrimination Act of 2008. Harvard Law Review, 122(3), 1038–1045.Google Scholar
  31. Hedgeco, A. (1996). Genetic catch-22: Testing, risk and private health insurance. Business & Professional Ethics Journal, 15(2), 69–86.Google Scholar
  32. Herman, B. (1993). The practice of moral judgment. New York: Harvard University Press.Google Scholar
  33. Human Genome Project/Write. (2016). Wikipedia.org https://en.wikipedia.org/wiki/Human_Genome_Project_-_Write. Accessed October 28, 2016.
  34. Hunt, S. D., & Vitell, S. J. (1986). General theory of marketing ethics. Journal of Macromarketing, 6(Spring), 5–15.Google Scholar
  35. Hunt, S. D., & Vitell, S. J. (2006). The general theory of marketing ethics: A revision and three questions. Journal of Macromarketing, 26(2), 1–11.Google Scholar
  36. IRMI (International Risk Management Institute). (2016). Retrieved April 30, 2016 from https://www.irmi.com/online/insurance-glossary/terms/a/adverse-selection.aspx
  37. Joly, Y., Braker, M., & Huynh, M. (2010). Genetic discrimination in private insurance: Global perspectives. New Genetics and Society, 29(4), 351–368.Google Scholar
  38. Jonas, H. (1979). Das Prinzip Verantwortung: Versuch einer Ethik für die technologische Zivilisation. Frankfurt am Main: Suhrkamp.Google Scholar
  39. Jonas, H. (1985). Technik, Medizin und Ethik: Zur Praxis des Prinzips Verantwortung. Frankfurt am Main: Insel.Google Scholar
  40. Jonas, H. (1994). Naturwissenschaft versus Natur-Verantwortung? Hans Jonas im Gespräch mit Eike Gebhardt. In D. Böhler (Ed.), Ethik für die Zukunft: Im Diskurs mit Hans Jonas (pp. 197–212). München: Beck.Google Scholar
  41. Jones, T. M. (1991). Ethical decision making by individuals in organizations: An issue contingent model. Academy of Management Review, 16(2), 366–395.Google Scholar
  42. Kant, I. (1965). Grundlegung zur Metaphysik der Sitten (Foundations of the metaphysics of morals). (Original publication 1783). Hamburg: Felix Meiner Verlag.Google Scholar
  43. Laczniak, G., & Murphy, P. (1993). Ethical marketing decisions: The higher road. Toronto: Allyn and Bacon.Google Scholar
  44. Laczniak, G. R., & Murphy, P. E. (2006). Normative perspectives for ethical and socially responsible marketing. Journal of Macromarketing, 26(2), 154–177.Google Scholar
  45. Laczniak, G., & Murphy, P. (2008). Distributive justice: Pressing questions, emerging Directions, and the Promise of Rawlsian analysis. Journal of Macromarketing, 28(1), 5–11.Google Scholar
  46. Landes, X. (2015). How fair is actuarial fairness? Journal of Business Ethics, 128, 519–533.Google Scholar
  47. McPherson, E. (2006). Genetic diagnosis and testing in clinical practice. Clinical Medicine & Research, 4(2), 123–129.Google Scholar
  48. Mill, S. J. (1979). Utilitarianism. (Original publication 1863), Indianapolis: Liberal Arts Press.Google Scholar
  49. Murphy, P. (1999). Character and virtue ethics in international marketing: An agenda for managers, researchers and educators. Journal of Business Ethics, 18(1), 107–124.Google Scholar
  50. Murphy, P., Laczniak, G., Bowie, N., & Klein, T. (2005). Ethical marketing. Upper Saddle River, NJ: Pearson Education.Google Scholar
  51. Murray, T. H. (1992). Genetics and the moral mission of health insurance. Hastings Center Report, 22(6), 12–17.Google Scholar
  52. Murray, T. H. (1997). Genetic exceptionalism and “future diaries”: Is genetic information different from other medical information? In M. Rothstein (Ed.), Genetic secrets: Protecting privacy and confidentiality in the genetic era. New Haven: Yale University Press.Google Scholar
  53. NIH (National Institutes of Health. (2016). Genetic testing: How it is used for healthcare. Retrieved April 17, 2016 from https://report.nih.gov/nihfactsheets/ViewFactSheet.aspx?csid=43
  54. Nill, A., Aalberts, R. J., Li, H., & Schibrowsky, J. (2015). New telecommunication technologies, big data, and online behavioral advertising: do we need an ethical analysis? In A. Nill (Ed.), Handbook on ethics and marketing. Cheltenham, UK and Northampton, MA, USA: Edward Elgar Publishing. doi:10.4337/978178003435. ISBN 987-1-78100-3428.Google Scholar
  55. Nill, A., & Schibrowsky, J. (2007). Marketing ethics research: A systematic review of the literature. Journal of Macromarketing, 27(2), 256–273.Google Scholar
  56. Oster, E., Shoulson, I., Quaid, K., & Ray Dorsey, E. (2010). Genetic adverse selection: Evidence from long-term care and Huntington’s disease. Journal of Public Economics, 94, 1041–1050.Google Scholar
  57. Otlowski, M., Taylor, S., & Bombard, Y. (2012). Genetic discrimination: International perspectives. Annual Review of Genomics and Human Genetics, 13, 433–454.Google Scholar
  58. Pettypiece, S., & Robertson, J. (2014). Did you know you had diabetes? It’s all over the internet. Available online at: http://www.bloomberg.com/news/2014-09-11/how-big-data-peers-inside-your-medicine-chest.html
  59. Radetzki, M., Radetzki, M., & Juth, N. (2003). Genes and insurance. Cambridge, UK: Cambridge University Press.Google Scholar
  60. Rawls, J. (1971). A theory of justice. Cambridge, MA: Harvard University Press.Google Scholar
  61. Ricoeur, P. (1990). On John Rawls’ a theory of justice: Is a pure procedural theory of justice possible? International Social Science Journal, 42(4), 553–564.Google Scholar
  62. Roberts, J. (2010). Preempting discrimination: Lessons from the genetic information nondiscrimination act. Vanderbilt Law Review, 63(2), 439–490.Google Scholar
  63. Rochman, B. (2017). The gene machine: How genetic technologies are changing the way we have kids. Scientific American: Farrar, Straus & Giraux.Google Scholar
  64. Rothschild, M., & Stiglitz, J. (1976). Equilibrium in competitive insurance markets: An essay on the economics of imperfect information. Quarterly Journal of Economics, 90, 629–649.Google Scholar
  65. Rothstein, M. (1999a). Why treating genetic information separately is a bad idea. Texas Review of Law & Politics, 4(1), 33–38.Google Scholar
  66. Rothstein, M. (1999b). Behavioral genetic determinism: Its effects on culture and law. In R. Carson & M. Rothstein (Eds.), Behavioral genetics. Baltimore: The Johns Hopkins University Press.Google Scholar
  67. Rothstein, M. (2007). Genetic exceptionalism and legislative pragmatism. Journal of Law, Medicine & Ethics, 35, 59–65.Google Scholar
  68. Rothstein, M. (2008a). Currents in contemporary ethics. GINA, the ADA, and genetic discrimination in employment. Journal of Law, Medicine & Ethics, 36(4), 837–840.Google Scholar
  69. Rothstein, M. (2008b). Currents in contemporary ethics. Is GINA worth the wait? Journal of Law, Medicine & Ethics, 36(1), 174–178.Google Scholar
  70. Rothstein, M. (2013). Epigenetic exceptionalism. Journal of Law, Medicine & Ethics, 41(3), 733–736.Google Scholar
  71. Schlegelmilch, B. (1998). Marketing ethics: An international perspective. London: Thomson Learning.Google Scholar
  72. Singer, P. (1986). Applied ethics. New York: Oxford University Press.Google Scholar
  73. Sun, L. (2017). Employees who decline genetic testing could face penalties under proposed bill.Google Scholar
  74. Suter, S. (2001). The allure and peril of genetic exceptionalism: Do we need special genetics legislation? Washington University Law Review, 79(3), 669–749.Google Scholar
  75. Tracer, Z., & Doherty, K. (2016). Aetna CEO says young people pick weekend beer over Obamacare. Retrieved November 5, 2016 from http://www.bloomberg.com/news/articles/2016-10-25/aetna-says-obamacare-plans-aren-t-worth-it-to-healthy-people
  76. Vaughn Switzer, J. (2003). Disabled rights: American disability policy and the fight for equality. Washington: Georgetown University Press.Google Scholar
  77. Vitell, S., & Hunt, S. (2015). The general theory of marketing ethics: Consumer ethics and intentions issues. In A. Nill (Ed.), Handbook on ethics and marketing. Cheltenham, UK and Northampton, MA, USA: Edward Elgar Publishing. doi:10.4337/978178003435. ISBN 987-1-78100-3428.Google Scholar
  78. Walker, F. (2007). Huntington’s disease. Lancet, 369(9557), 218–228.Google Scholar
  79. Walton, C. (1988). The moral manager. Cambridge, MA: Ballinger.Google Scholar
  80. Webster’s New Universal Unabridged Dictionary. (1992). New York: Barnes and Noble.Google Scholar
  81. Werner, M. (2003). Hans Jonas’ Prinzip Verantwortung. In M. Düwell & K. Steigleder (Eds.), Eine Einführung (pp. 41–56). Frankfurt a. M.: Suhrkamp.Google Scholar
  82. Worthham, L. (1986). Insurance classification: Too important to be left to actuaries. University of Michigan Law Reform, 19, 349–423.Google Scholar
  83. Zick, C., Charles Mathers, J., Roberts, S., Cook-Deegan, R., Pokorski, R., & Green, R. (2005). Genetic testing for Alzheimer’s disease and its impact on insurance purchasing. Health Affairs, 24(2), 483–490.Google Scholar
  84. Zwart, H. (2015). Human genome project: History and assessment. International Encyclopedia of the Social & Behavioral Sciences, 11(2), 311–317.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2017

Authors and Affiliations

  1. 1.Department of Marketing and International Business, Lee Business SchoolUniversity of Nevada Las VegasLas VegasUSA
  2. 2.Department of Marketing, College of Business AdministrationMarquette UniversityMilwaukeeUSA
  3. 3.Department of Finance, Lee Business SchoolUniversity of Nevada Las VegasLas VegasUSA

Personalised recommendations